Share this article on:

Leishmaniasis Recidivans in Pediatric Patients

Ardic, Nurittin MD; Yesilova, Yavuz MD; Gunel, Ilkin Elif MD; Ardic, Ilknur Nihal

The Pediatric Infectious Disease Journal: May 2017 - Volume 36 - Issue 5 - p 534
doi: 10.1097/INF.0000000000001489
Letters to the Editors

Department of Medical Microbiology, Faculty of Medicine, Baskent University, Ankara, Turkey

Department of Dermatology, Special Lokman Physician Hospital, Van, Turkey

Department of Pediatric, Faculty of Medicine, Hacettepe University, Ankara, Turkey

School of Medicine, Gazi University, Ankara, Turkey

The authors have no funding or conflicts of interest to disclose.

Address for correspondence: Nurittin Ardic, MD. E-mail:

Back to Top | Article Outline

To the Editors:

Due to the war in Syria, the epidemiology of leishmaniasis and species distribution of the causative agents are rapidly changing as a result of migration of refugees from Syria to neighboring Turkey and the other countries. Unusual manifestations of the disease frequently occur, which complicates the diagnosis and treatment. This letter aims to reflect our experience with leishmaniasis recidivans (LR) in pediatric cases, the most prevalent group for cutaneous leishmaniasis (CL).

LR is a rare clinical form that occurs following years after resolution of localized CL because of reactivation of the dormant parasites.1 In the Old World, LR is usually caused by Leishmania tropica, the main causative agent for CL in Turkey, an endemic country.2 The scarcity of the parasites in skin biopsy complicates the diagnosis, especially for patients in a nonendemic region. The lesions become destructive and disfiguring after many years because most of the patients may be resistant to regular treatment.1

The pathogenesis of LR is still unclear. Receiving incomplete course of treatment may play a role in resistance and recurrence of the lesions. The host immunologic status, especially defective Th1-type immune response, can also result in reduction of parasitic clearance.3

In our study covering 14-years and 8786 patients, we observed LR in 2,·29% of the pediatric CL patients, most commonly in 0 to 5-year-old group (4.34%). A more immature immune system relative to older children could explain this observation. This age group responded better than other groups to intralesional treatment, although follow-up observation is required because they were more prone to develop recidivans.2 Surprisingly, Sharifi et al1 reported more prevalent LR in the 6 to 10-year-old group.

We observed that the population in the refugee camps mostly consists of pediatric age groups. Thus, pediatric population is at risk of the diseases, indirectly LR.

In LR, the high rates resistant to the first line drugs necessitate new treatment alternatives. Successful results have been observed with combination therapies.4 Another recommended method is immunomodulatory therapy for LR.3 We suggest inducing the immune system to increase parasitic clearance or inhibiting the parasite-driven milieu which promotes parasite survival.

Our experience and some studies using thermotherapy, such as radiofrequency, thermotherapy and hand-held exothermic crystallization thermotherapy showed highly effective clinical cure rates in CL.5 Subsequently, a thermo-therapeutic approaching can overcome the treatment problem in LR cases because of thermo-sensitivities of the dermatotrophic L. tropica species.

Considerable progress has been made during the past decades to develop a vaccine against leishmaniasis. Depending on local epidemiologic data vaccine should be given priority for LR for children.

In conclusion, LR is an important clinical manifestation of CL with its higher morbidity, more duration to recover and more resistance to the standard therapy regimens. Local epidemiologic data should be considered in treatment decisions.

Nurittin Ardic, MD

Department of Medical Microbiology

Faculty of Medicine

Baskent University

Ankara, Turkey

Yavuz Yesilova, MD

Department of Dermatology

Special Lokman Physician Hospital

Van, Turkey

Ilkin Elif Gunel, MD

Department of Pediatric

Faculty of Medicine

Hacettepe University

Ankara, Turkey

Ilknur Nihal Ardic

School of Medicine

Gazi University

Ankara, Turkey

Back to Top | Article Outline


1. Sharifi I, Fekri AR, Aflatoonian MR, et al. Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006. Int J Dermatol. 2010;49:557–561.
2. Aksoy M, Doni N, Ozkul HU, et al. Pediatric cutaneous leishmaniasis in an endemic region in Turkey: a retrospective analysis of 8786 cases during 1998-2014. PLoS Negl Trop Dis. 2016;10:e0004835.
3. Marovich MA, Lira R, Shepard M, et al. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin Infect Dis. 2001;33:1076–1079.
4. Esfandiarpour I, Dabiri SH. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol. 2007;46:848–852.
5. Valencia BM, Miller D, Witzig RS, et al. Novel low-cost thermotherapy for cutaneous leishmaniasis in Peru. PLoS Negl Trop Dis. 2013;7:e2196.
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.